Gilead Sciences Inc. (GILD)

76.58
0.96 1.20
NASDAQ : Health Technology
Prev Close 77.54
Open 76.75
Day Low/High 76.20 / 77.53
52 Wk Low/High 60.89 / 85.97
Volume 8.56M
Avg Volume 21.89M
Exchange NASDAQ
Shares Outstanding 1.25B
Market Cap 93.30B
EPS 4.20
P/E Ratio 19.08
Div & Yield 2.72 (3.51%)
Gilead Has Become and Will Be a Volatile Name

Gilead Has Become and Will Be a Volatile Name

I would consider any entry a trade, and not an investment.

Shares of Gilead Could Surge to the $88 Area in the Near-Term

Shares of Gilead Could Surge to the $88 Area in the Near-Term

Any modest intraday dip is probably a buying opportunity.

There's Now Reason, and Science, to Playing GILD

There's Now Reason, and Science, to Playing GILD

Here's what the charts say about entering Gilead Sciences.

Gilead Sciences Coronavirus Treatment News Could Lead to Key Upside Breakout

Gilead Sciences Coronavirus Treatment News Could Lead to Key Upside Breakout

Company has an agreement with Chinese authorities to study the effectiveness of an experimental Ebola and SARS treatment on coronavirus patients.

This Drugmaking Dividend Stock Due for Shot in the Arm

This Drugmaking Dividend Stock Due for Shot in the Arm

Gilead offers a nearly 4% yield and looks ready to return to growth.

Target the Bullish Pattern in Gilead Sciences

Target the Bullish Pattern in Gilead Sciences

Also, another buy setup is emerging in Nutanix.

Alibaba, Salesforce, Constellation Software Make RBC's List of Top 2020 Picks

Alibaba, Salesforce, Constellation Software Make RBC's List of Top 2020 Picks

RBC analysts expect Alibaba and Salesforce to continue posting strong double-digit sales growth, and remain fans of Constellation's M&A-driven growth strategy.

3 Biotech Stocks With the Best-Looking Charts

3 Biotech Stocks With the Best-Looking Charts

Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.

Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets

Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets

The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.

Gilead Rated New Hold at SunTrust

Markets Looking Good

"Politics: "Poli" a Latin word meaning "many" and "tics" meaning "bloodsucking creatures" - Robin Williams Markets are looking good a half hour into the trading day. All the major indices are nicely in the black with the NASDAQ up approximately one ...

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

I'm Looking at Gilead and Merck for Buy Entry Positions

I'm Looking at Gilead and Merck for Buy Entry Positions

Let's see if either of these names provide an entry this week.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

3 Autopilot Funds for a High-Yield Portfolio

3 Autopilot Funds for a High-Yield Portfolio

This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Gilead Sciences Is Regaining Its Shine

Gilead Sciences Is Regaining Its Shine

Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.

Are These Stocks the Best of the Best?

Are These Stocks the Best of the Best?

Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.

Seattle Genetics Struggles as Other Biotech Stocks Rise

Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...

Inverted Yield Curve Has Lost a Lot of Its Predictive Power

The market has given up some of its early gains, but the major indices are all still in the black. Homebuilders have given up their 1% rally early today and now are flat. The Atlanta Fed's GDPNow has the economy growing 1.7% now from the last readin...

Before the Open

Less than a hour to go before the market open as we await the last trading day of the first quarter. Pre-market futures are still pointing to a up opening. Gilead Sciences is up some 2% this morning after developmental partner Galapagos announced so...

The Real Money Post Industrial Average Continues to Soar

The Real Money Post Industrial Average Continues to Soar

The RMPIA rose 10.5% during the first half of the current quarter.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.